相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CDK7 controls E2F-and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma
Yao Yao et al.
BLOOD (2023)
The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma
Steven Findlay et al.
BLOOD ADVANCES (2023)
PRPS2 mutations drive acute lymphoblastic leukemia relapse through influencing PRPS1/2 hexamer stability
Lili Song et al.
BLOOD SCIENCE (2023)
Hallmarks of Cancer: New Dimensions
Douglas Hanahan
CANCER DISCOVERY (2022)
Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma
Laura A. Evans et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
Kristine Misund et al.
LEUKEMIA (2022)
Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma
Hongmei Jiang et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2022)
Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions
Seiichi Okabe et al.
BIOMARKER RESEARCH (2022)
An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapse
Lorenz Bartsch et al.
BMC GENOMIC DATA (2022)
Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13
Ting Du et al.
LEUKEMIA (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
Almudena Garcia-Ortiz et al.
CANCERS (2021)
Metabolic Reprogramming Induces Immune Cell Dysfunction in the Tumor Microenvironment of Multiple Myeloma
Shaojie Wu et al.
FRONTIERS IN ONCOLOGY (2021)
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Mehmet Kemal Samur et al.
NATURE COMMUNICATIONS (2021)
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Karthik Dhatchinamoorthy et al.
FRONTIERS IN IMMUNOLOGY (2021)
NSDHL promotes triple-negative breast cancer metastasis through the TGFβ signaling pathway and cholesterol biosynthesis
Mengting Chen et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis
Lisa C. Holthof et al.
CLINICAL CANCER RESEARCH (2021)
Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis
Marwa Tantawy et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Prognostic and predictive biomarker developments in multiple myeloma
Craig T. Wallington-Beddoe et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
H3K27ac-induced lncRNA PAXIP1-AS1 promotes cell proliferation, migration, EMT and apoptosis in ovarian cancer by targeting miR-6744-5p/PCBP2 axis
Yimin Ma et al.
JOURNAL OF OVARIAN RESEARCH (2021)
Chromosome 1q21 abnormalities in multiple myeloma
Timothy M. Schmidt et al.
BLOOD CANCER JOURNAL (2021)
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Suchit Jhunjhunwala et al.
NATURE REVIEWS CANCER (2021)
NOTCH1-driven UBR7 stimulates nucleotide biosynthesis to promote T cell acute lymphoblastic leukemia
Shashank Srivastava et al.
SCIENCE ADVANCES (2021)
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma
Adam D. Cohen et al.
CLINICAL CANCER RESEARCH (2020)
NAD(P)-dependent steroid dehydrogenase-like is involved in breast cancer cell growth and metastasis
So-Hyun Yoon et al.
BMC CANCER (2020)
Nine glycolysis-related gene signature predicting the survival of patients with endometrial adenocarcinoma
JinHui Liu et al.
CANCER CELL INTERNATIONAL (2020)
MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma
Qiang Wang et al.
BLOOD (2020)
Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma
Sho Ikeda et al.
CANCER SCIENCE (2020)
Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma
Nadine Abdallah et al.
CLINICAL CANCER RESEARCH (2020)
PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker
Timothy M. Horton et al.
SCIENTIFIC REPORTS (2020)
Antigen processing and presentation in cancer immunotherapy
Maxwell Y. Lee et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Plasma cells: You are what you eat
Lucas D'Souza et al.
IMMUNOLOGICAL REVIEWS (2019)
The Crosstalk Between Cell Adhesion and Cancer Metabolism
Barbara Sousa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Cell-Cycle-Dependent Phosphorylation of PRPS1 Fuels Nucleotide Synthesis and Promotes Tumorigenesis
Xiaoqian Jing et al.
CANCER RESEARCH (2019)
Identification of novel cell glycolysis related gene signature predicting survival in patients with endometrial cancer
Zi-Hao Wang et al.
CANCER CELL INTERNATIONAL (2019)
Aurora-A mediated phosphorylation of LDHB promotes glycolysis and tumor progression by relieving the substrate-inhibition effect
Aoxing Cheng et al.
NATURE COMMUNICATIONS (2019)
Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma
Mailee Huynh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Resistance to proteasome inhibitors and other targeted therapies in myeloma
Craig T. Wallington-Beddoe et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Tathiane M. Malta et al.
CELL (2018)
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Jung-Mao Hsu et al.
NATURE COMMUNICATIONS (2018)
Targeting Tumor Metabolism: A New Challenge to improve immunotherapy
Soumaya Kouidhi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016
Andrew J. Cowan et al.
JAMA ONCOLOGY (2018)
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang et al.
NATURE MEDICINE (2018)
Histone methylation regulator PTIP is required to maintain normal and leukemic bone marrow niches
Prosun Das et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
NF-κB, inflammation, immunity and cancer: coming of age
Koji Taniguchi et al.
NATURE REVIEWS IMMUNOLOGY (2018)
A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System
Sung-Hoon Jung et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
PTIP chromatin regulator controls development and activation of B cell subsets to license humoral immunity in mice
Dan Su et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
Pornpimol Charoentong et al.
CELL REPORTS (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy
Hyungwoo Cho et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Dysfunctional T cell metabolism in the tumor microenvironment
Kathryn E. Beckermann et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2017)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al.
BLOOD (2016)
Lactate Dehydrogenase B Controls Lysosome Activity and Autophagy in Cancer
Lucie Brisson et al.
CANCER CELL (2016)
Multiple myeloma and persistence of drug resistance in the age of novel drugs
Sabna Rajeev Krishnan et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation
Xinjian Li et al.
NATURE CELL BIOLOGY (2016)
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
Etienne Becht et al.
GENOME BIOLOGY (2016)
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System
Rowan Kuiper et al.
BLOOD (2015)
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
David H. Vesole et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma
Patricia Maiso et al.
CANCER RESEARCH (2015)
A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells
Zi-Jie Long et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Mitochondrial proteomics with siRNA knockdown to reveal ACAT1 and MDH2 in the development of doxorubicin-resistant uterine cancer
Yi-Wen Lo et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance
Yunhua He et al.
LEUKEMIA RESEARCH (2015)
Modulation of Cell Metabolic Pathways and Oxidative Stress Signaling Contribute to Acquired Melphalan Resistance in Multiple Myeloma Cells
Kamila Anna Zub et al.
PLOS ONE (2015)
Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma
Kelley Salem et al.
REDOX BIOLOGY (2015)
FastRFunctions for Robust Correlations and Hierarchical Clustering
Peter Langfelder et al.
Journal of Statistical Software (2015)
Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
Kevin R. Kelly et al.
INVESTIGATIONAL NEW DRUGS (2014)
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Emilia Caputo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
IMWG consensus on risk stratification in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2014)
pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels
Paul Geeleher et al.
PLOS ONE (2014)
Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance
Chi Kwan Tsang et al.
NATURE COMMUNICATIONS (2014)
Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines
Paul Geeleher et al.
GENOME BIOLOGY (2014)
Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL
Laura Mazzera et al.
BLOOD (2013)
Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib
W. Y. Sanchez et al.
BRITISH JOURNAL OF CANCER (2013)
NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers
Wen Zhou et al.
CANCER CELL (2013)
Aurora A kinase (AURKA) in normal and pathological cell division
Anna S. Nikonova et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2013)
Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy
Samuel K. McBrayer et al.
BLOOD (2012)
Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
E. Claire Dees et al.
CLINICAL CANCER RESEARCH (2012)
Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
Donna M. Weber et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
A gene expression signature for high-risk multiple myeloma
R. Kuiper et al.
LEUKEMIA (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
Cancer stem cells and metastasis
Katia Sampieri et al.
SEMINARS IN CANCER BIOLOGY (2012)
Multiple Myeloma
Jacob Laubach et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored
Damian Szklarczyk et al.
NUCLEIC ACIDS RESEARCH (2011)
Anovel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
Guellue Goerguen et al.
BLOOD (2010)
PTIP Promotes Chromatin Changes Critical for Immunoglobulin Class Switch Recombination
Jeremy A. Daniel et al.
SCIENCE (2010)
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Susanne M. A. Lens et al.
NATURE REVIEWS CANCER (2010)
Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation
Nukhet Aykin-Burns et al.
BIOCHEMICAL JOURNAL (2009)
Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progression
Jui Dutta-Simmons et al.
BLOOD (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
RNA Polymerase III Detects Cytosolic DNA and Induces Type I Interferons through the RIG-I Pathway
Yu-Hsin Chiu et al.
CELL (2009)
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Ashraf Badros et al.
CLINICAL CANCER RESEARCH (2009)
RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate
Andrea Ablasser et al.
NATURE IMMUNOLOGY (2009)
WGCNA: an R package for weighted correlation network analysis
Peter Langfelder et al.
BMC BIOINFORMATICS (2008)
Mechanisms of proteasome inhibitor action and resistance in cancer
David J. McConkey et al.
DRUG RESISTANCE UPDATES (2008)
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul Richardson et al.
LEUKEMIA & LYMPHOMA (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy
Erwan Thouennon et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Targeting aurora kinases as therapy in multiple myeloma
Yijiang Shi et al.
BLOOD (2007)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
George Mulligan et al.
BLOOD (2007)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia
Xianhua Cao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Roles of aurora kinases in mitosis and tumorigenesis
Jingyan Fu et al.
MOLECULAR CANCER RESEARCH (2007)
Decision curve analysis: A novel method for evaluating prediction models
Andrew J. Vickers et al.
MEDICAL DECISION MAKING (2006)
Reductive detoxification of arylhydroxylamine carcinogens by human NADH cytochrome b5 reductase and cytochrome b5
Joseph R. Kurian et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2006)
Cell adhesion and signalling by cadherins and Ig-CAMs in cancer
U Cavallaro et al.
NATURE REVIEWS CANCER (2004)
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
CS Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
A long-term study of prognosis in monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
